{
    "id": 1922,
    "fullName": "STK11 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "STK11 loss indicates loss of the STK11 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6794,
        "geneSymbol": "STK11",
        "terms": [
            "STK11",
            "hLKB1",
            "LKB1",
            "PJS"
        ]
    },
    "variant": "loss",
    "createDate": "09/26/2014",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5597,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).",
            "molecularProfile": {
                "id": 1882,
                "profileName": "STK11 loss"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5119,
                    "pubMedId": 26833127,
                    "title": "STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26833127"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1111,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, PMID: 18006825).",
            "molecularProfile": {
                "id": 1882,
                "profileName": "STK11 loss"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 853,
                    "pubMedId": 18006825,
                    "title": "Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18006825"
                },
                {
                    "id": 854,
                    "pubMedId": 17062558,
                    "title": "Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17062558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 601,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).",
            "molecularProfile": {
                "id": 18395,
                "profileName": "PTEN loss STK11 loss"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 350,
                    "pubMedId": 24322983,
                    "title": "A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24322983"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5405,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).",
            "molecularProfile": {
                "id": 20860,
                "profileName": "ERBB2 act mut STK11 loss"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5047,
                    "pubMedId": 25436981,
                    "title": "Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25436981"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5451,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378).",
            "molecularProfile": {
                "id": 20914,
                "profileName": "STK11 D194E STK11 loss"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5063,
                    "pubMedId": 21189378,
                    "title": "mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21189378"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",
            "molecularProfile": {
                "id": 28317,
                "profileName": "KRAS mut STK11 loss TP53 loss"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).",
            "molecularProfile": {
                "id": 28318,
                "profileName": "KRAS G12D STK11 loss"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18672,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment resulted in tumor regression in all the tumors in a mouse model harboring KRAS G12D and loss of STK11 (PMID: 31534020).",
            "molecularProfile": {
                "id": 28318,
                "profileName": "KRAS G12D STK11 loss"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1882,
            "profileName": "STK11 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 8390,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "STK11 loss"
                },
                {
                    "id": 8389,
                    "name": "mTOR Inhibitor",
                    "profileName": "STK11 loss"
                }
            ]
        },
        {
            "id": 18395,
            "profileName": "PTEN loss STK11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20860,
            "profileName": "ERBB2 act mut STK11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20914,
            "profileName": "STK11 D194E STK11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28317,
            "profileName": "KRAS mut STK11 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28318,
            "profileName": "KRAS G12D STK11 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}